|
|
James Bicher MD, President - Bicher Cancer Institute
Dr James Bicher was born in San Cristobal, Santa Fe, Argentina. He study in the University of Buenos Aires Medical School, and finalized his medical studies received his MD degree in the MD Hadassah Medical School, Jerusalem, Israel in 1962.
Dr James Bicher did his medical Internship in Beilinson Hospital, Petah-Tiqya, Israel.
James Bicher MD did his Radiation Therapy Residency in Roswell Park Memorial Institute, Buffalo, New York, and University of Arkansas for Medical Sciences in Little Rock, Arkansas, in the period of 1974 to 1977.
James Bicher MD obtained his ABR certification in Radiation Therapy in 1977, and hols a California Medical license since 1981.
Dr James Bicher is Director of Valley Cancer Institute in Panorama City and Culver City, Los Angeles area, since 1984, and Bicher Cancer Institute in Los Angeles since 2010, and practice Hyperthermia combined with low-dose-radiation since 1884.
James Bicher MD is one of the founders of several Hyperthermia Societies, like ASCHO and ICHS, International Clinical Hyperthermia Society. Dr James Bicher regularly participates on international meetings of different hyperthermia societies, like STM, Society for Thermal Medicine, the ICHS, the German Hyperthermia Society, and others. He presents papers on the clinical use of hyperthermia on those meetings.
Dr James Bicher MD has developed a very effective protocol to treat cancer, which is very effective on head and neck cancers, Throat cancer, Base of Tongue cancer, Breast Cancer, Inflammatory Breast Cancer, Prostate Cancer, and Annal Cancer.
Most patients with Prostate Cancer who are treated with Dr Bicher’s protocol, Hyperthermia combined with low-dose-fractionated-radiation do not have the sexual side effects of impotency and loss of libido.
Is interesting to note that the success rate of patients with stage II annal cancer treated with hyperthermia and low-dose-radiation is about 80 , which means that Farrah Faucet had much better chances of prolong her life or even be cancer free, had she chosen Hyperthermia s her annal cancer treatment.
The average success rate of Dr James Bicher MD Hyperthermia Cancer Treatment protocol is about 80 for early stages , as well as the 5 years survival rate.
See http://vci.org or http://bichercancerinstitute.com for detailed information, patients testimonies videos, and treatment results.
Some of James Bicher MD publications:
James Bicher MD: http://vci.org
James Bicher MD: http://bichercancerinstitute.com
James Bicher MD: http://www.jameshaimbicher-md.org/
James Bicher MD: http://www.jameshaimbicher-md.org/james_haim_bicher_md_publications/james_haim_bicher_md_publications.htm
James Bicher's Companies
-
-
|
|
Valley Cancer Institute
1984 - 2011
- Los Angeles, California
Director
Practice Hyperthermia combined with Low_Dose_Radiation cancer treatment
|
James Bicher's Publications
-
|
Blood Cell Aggregation in Thrombic Processes, Ed. W Seegers, Charles C Thomas- James Bicher MD
May, 1972
James Bicher MD
|
-
|
Oxygen Transport to Tissue: Instrumentation, Methods and Physiology, Plenum Press - James Bicher MD
May, 1973
|
-
|
Oxygen Transport to Tissue: Pharmacology, Mathematical Studies and Neonatology, Plenum Press - James Bicher MD
May, 1973
|
-
|
Oxygen Transport to Tissue: III, Plenum Press - James Bicher MD
May, 1978
|
-
|
Hyperthermia, Plenum Press - James Bicher MD
May, 1982
|
-
|
Oxygen Transport to Tissue: IV, Plenum Press - James Bicher MD
May, 1983
|
-
|
Oxygen Transport to Tissue: VII, Plenum Press - James Bicher MD
May, 1984
|
-
|
Consensus on Hyperthermia for the 1990s, Plenum Press - James Bicher MD
May, 1990
|
James Bicher's Presentations
-
-
-
|
Therapeutic Advantage of Hyperfractionated Thermoradiotherapy (HTRT) Over Conventional Radiation in Superficial Tumors treated De Novo with Curative Intent , ICHS 2010 - James Bicher MD, Koln, Germany
May, 2010
Material and Methods: Fractionation used involved daily hyperthermia treatments in conjunction with each radiation fraction. Radiation daily doses are progressively decreased from 180 to 100 cGy resulting in protracted treatment time that decreases the isoeffect biological equivalent dose by 15% to 25%. This decrease is compensated by the increased number of hyperthermia fractions which potentiates each radiation dose. Treatment is continued until an objective complete response is attained, or failure determined. 40 breast patients, 27 head and neck and 22 prostate patients were treated with a follow up of two to five years. All patients were early stage (III-a or less).
|
-
|
Hyperfractionated Thermoradiotheray (HTRT), STM 2010 - James Bicher MD, Clearwater, Florida
May, 2010
Fractionation used involved daily hyperthermia treatments in conjunction with each radiation fraction. Radiation daily doses are progressively decreased from 180 to 100 cGy resulting in protracted treatment time that decreases the isoeffect biological equivalent dose by 15% to 25%. This decrease is compensated by the increased number of hyperthermia fractions which potentiates each radiation dose. Treatment is continued until an objective complete response is attained, or failure determined.
|
-
|
Therapeutic Advantage of Hyperfractioned Thermoradiotherapy (HTRT) Over Conventional Radiation in Superficial Tumors treated De Novo with Curative Intent, STM 2011 - James Bicher MD, New Orleans, Louisiana
May, 2011
Material and Methods: Fractionation used involved daily hyperthermia treatments in conjunction with each radiation fraction. Radiation daily doses are progressively decreased from 180 to 100 cGy resulting in protracted treatment time that decreases the isoeffect biological equivalent dose by 15% to 25%. This decrease is compensated by the increased number of hyperthermia fractions which potentiates each radiation dose. Treatment is continued until an objective complete response is attained, or failure determined. 40 breast patients, 27 head and neck and 22 prostate patients were treated with a follow up of two to five years. All patients were early stage (III-a or less)
|
|
